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Abstract 
Drug combinations are frequently used for the treatment of cancer patients in order to increase 
efficacy, decrease adverse side effects, or overcome drug resistance. Given the enormous number 
of drug combinations, it is cost- and time-consuming to screen all possible drug pairs 
experimentally. Currently, it has not been fully explored to integrate multiple networks to predict 
synergistic drug combinations using recently developed deep learning technologies. In this study, 
we proposed a Graph Convolutional Network (GCN) model to predict synergistic drug 
combinations in particular cancer cell lines. Specifically, the GCN method used a convolutional 
neural network model to do heterogeneous graph embedding, and thus solved a link prediction task. 
The graph in this study was a multimodal graph, which was constructed by integrating the drug-
drug combination, drug-protein interaction, and protein-protein interaction networks. We found that 
the GCN model was able to correctly predict cell line-specific synergistic drug combinations from 
a large heterogonous network. The majority (30) of the 39 cell line-specific models show an area 
under the receiver operational characteristic curve (AUC) larger than 0.80, resulting in a mean 
AUC of 0.84. Moreover, we conducted an in-depth literature survey to investigate the top predicted 
drug combinations in specific cancer cell lines and found that many of them have been found to 
show synergistic antitumor activity against the same or other cancers in vitro or in vivo. Taken 
together, the results indicate that our study provides a promising way to better predict and optimize 
synergistic drug pairs in silico. 
Keywords: Synergistic drug combination, Cancer, Cell line, Graph convolutional network, 
heterogenous network. 
 
 
1. Introduction 
Drug combinations, also known as combinatorial therapies, are frequently prescribed to treat 
patients with complex diseases especially cancers [1,2], which have been driven by many 
mechanisms concurrently [3]. The rationale of drug combination is that targeting multiple 
molecular mechanisms in cancer cells simultaneously can typically increase the potency of the 
treatment [1,2]. Thus, compared to monotherapies (i.e., single drug treatments), whose 
effectiveness may be limited, drug combinations have been reported with the potential to increase 
efficacy [1,2], decrease adverse side effects [4], or overcome drug resistance in cancer treatment 
[5]. However, a concurrent use of multiple drugs may sometimes cause adverse effects [6]. For 
example, the addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based 
chemotherapy has been shown to lead to an increased toxicity and decreased progression free 
survival of metastatic colorectal cancer patients [6]. Therefore, it is critical to evaluate the effects 
of drug combinations in cancer cells and thereby identify those showing synergistic effects in a 
particular cancer type. Synergistic drug combinations exhibit greater total effect of the drugs than 
the additive effects of the individual drugs [7]. 
One of the challenges in studying drug synergy is that the possible number of drug 
combinations grows exponentially with the number of drugs under consideration, further expanded 
by the number of cancer types and drug dosages. Conventionally, effective drug combinations 
were proposed according to clinical trials, which are time- and cost-consuming, and what was 
worse, may expose patients to unnecessary or even harmful treatments [8,9]. More recently, high 
throughput screening (HTS) approaches have been extensively used to determine and evaluate 
effective combination strategies in a preclinical setting, which test an enormous number of drug 
combinations prescribed with different dosages and applied to different cancer cell lines [4,10,11]. 
An example is the study performed by O’Neil and collogues [4]. This study carried out 23,062 
experiments on 583 drug combinations across 39 cell lines from various cancer types, 
recapitulating in vivo response profiles. Although they don’t perfectly represent the original tumor 
tissues, cancer cell lines can be used to provide an alternative way for assessing the synergistic 
properties across drugs. Thus, data generated by HTS strategies enables the possibility of silico 
prediction of novel synergistic drug pairs, which can further guide in vitro and in vivo discovery 
of rational combination therapies. 
A number of computational methods have been developed to predict anti-cancer drug synergy 
using chemical information from drugs, or molecular data from cancer cell lines, or both. The 
approaches rang from traditional machine learning models to deep learning methods. Sidorov and 
collogues utilized two machine learning methods (random forest (RF) and extreme gradient 
boosting (XGBoost)) to develop models for drug synergy prediction [12]. The models took the 
physicochemical properties of drugs as input and were trained on a per-cell line basis, which means 
each method (RF or XGBoost) was used to generate a model for each cell line. The XGBoost 
method demonstrated a slightly better prediction performance than the RF technique when they 
were evaluated in a new data set. As shown in [7], given a drug pair comprising drugs A and B 
and a particular cell line C, a deep learning-based regression model (termed DeepSynergy) was 
developed using both the chemical descriptors for drugs A and drug B and the gene expression 
profiles of the cell line C to predict the synergy scores of  specific drug combinations on a given 
cell line. DeepSynergy demonstrated an improvement of 7.2% in its performance over Gradient 
Boosting Machines for drug synergy prediction task. Zhang and collogues [13] also proposed a 
deep learning-based model named AuDNNsynergy by integrating multi-omics data (i.e., the gene 
expression, copy number and genetic mutation data) from cancer cell lines to predict synergistic 
drug combinations. AuDNNsynergy outperformed the other four approaches, namely 
DeepSynergy, gradient boosting machines, random forests, and elastic nets. Other studies, such as 
Hsu et al. [14], explored gene set-based approaches to predict the synergy of drug pairs. However, 
there are limited works applying the recently developed graph convolutional network (GCN) 
approaches [15] to predict drug synergy in cancers by integrating multiple biological networks. 
This study tried to develop GCN models to predict synergistic drug combinations in cancer cell 
lines by performing heterogeneous graph embedding from an integrated drug-drug combination, 
drug-protein interaction, and protein-protein interaction network.  
2. Material and Methods 
2.1. Data collection 
Our study design is depicted in Fig.1. The GCN model for synergistic drug combination 
prediction was cell line-specific and based on three different types of subnetworks: drug-drug 
synergy (DDS) network, drug-target interaction (DTI) network, and protein-protein interaction 
(PPI) network. Data from various sources such as online databases and the published literature 
were collected to build the three networks (Table 1). Firstly, we obtained the DDS data from 
O’Neil et al.’s study [4]. This study contains 23,062 drug-drug combinations with the 
corresponding Loewe synergy scores tested across 38 drugs in 39 cell lines derived from 6 human 
cancer types. The Loewe synergy score is also termed as Loewe Additivity [16]. Secondly, the 
DTI data were acquired from the STITCH database [17], which provides voluminous interactions 
between chemical compounds and target proteins. More than 500,000 compounds and 8,900 
proteins consist of 8,083,600 interactions. Of these DTIs, we included those that have been 
validated experimentally. Thirdly, we collected the PPI data from two comprehensive open access 
repositories, the BioGRID database [18] and the STRING database [19]. We further enriched these 
two databases with two additional PPI networks published by Menche et al. [20] and Rolland et 
al. [21], resulting in a total of 719,402 experimentally validated physical interactions over 19,085 
unique proteins.  
The three types of subnetworks were used to construct a heterogenous network interactively. 
This final heterogeneous network is the intersection of heterogenous entities (i.e., proteins and 
drugs), and has their links from the three subnetworks [15]. Cell line specific networks were 
constructed by focusing on the links in a given cell line (Fig.2). In addition, only related PPIs and 
DTIs were preserved in a cell line-specific network. As a result, 39 cell line specific heterogeneous 
networks were established. 
Table 1 The data sources of three types of interactions 
Data sources Number of links Number of entities 
Ⅰ(DDS) 23,052 DDS 38 drugs, 39 cell lines 
Ⅱ(DTIs) 8,083,600 DTIs 519,022 drugs, 8,934 proteins, 
Ⅲ (PPIs) 719,402 PPIs 19,085 proteins 
 
 
 
Fig.1. The study design. (a) Data collection. The drug-drug synergy (DDS) data, the drug-target interaction (DTI) data, 
and the protein-protein interaction (PPI) data were collected for the three subnetworks. (b) Network construction. For 
a given cell line, the synergy scores of drug pairs were binarized to construct the DDS subnetwork, which together 
with the DTI and PPI networks was further built the cell line-specific heterogenous network. (c) Model inference. The 
heterogenous network for a specific cell line is the input of the GCN encoder. Each encoded node is then mapped to 
an embedding space for representing the drug-drug synergy prediction in the new space. (d) Model evaluation. The 
negative sampling method together the accuracy, AUC, and Pearson correlation coefficient metrics were used. (e) 
Exploration of embedding space. t-SNE method was used to find the distribution of synergistic drug combinations. 
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Fig.2. The cell line-specific heterogenous network derived from cell line CAOV3. The orange color represents the 
proteins (nodes) and their interactions (edges), the teal color represents the drugs (nodes) and their interactions 
(edges), and the olive color represents the interactions (edges) between the drugs and the proteins. 
 
2.2. Graph Convolutional Network Encoder 
As shown in [22], the prediction of synergistic drug combinations can be formulized as a link 
prediction problem using complex networks. In this study, we represented the different types of 
known links in the heterogeneous network belonging to each of the unique cell lines. Our research 
aim is to predict drug-drug synergic links using all the link information in the heterogeneous 
network [23]. The kind of prediction is related to semi-supervised learning in graphs such as GCN. 
The GCN model is a neural network that operates on graphs and enables learning over graph 
structures. It is widely used as an encoder in different deep learning architectures. An encoder is a 
tool for mathematical transformation to map information from a space to another space (i.e., the 
embedding space). In this study, the encoder is based on GCN by operating the complex network 
to extract vital information in the graph.  
To elucidate the GCN more clearly, the entities and their links in a network are usually 
represented by a defined graph G = (V, E), where V is a set of N nodes such as drugs and proteins, 
and E is a set of M edges such as drug-drug links and drug-protein links. These N nodes have 
numerical node feature vectors x1, x2,  x3, …, xN ∈ ℝd , where d is the dimension of the feature 
vector. As for the edges, for example, (𝒗𝒊 , 𝒗𝒋 ) represents the link between node 𝒗𝒊  and 𝒗𝒋 . 
Although the convolution procedure in the Euclidean space is well-defined, it is not well-defined 
in the graph because of the uncertainty of topological structures in different nodes. In regular 
Euclidean arrays such as matrices and pixels in images, convolutional neural network (CNN) is of 
great efficiency. However, when considering graphs, the traditional CNN model is not as powerful 
as it in lattices. Many approaches were proposed to solve this problem in the past several years. 
In 2016, Kipf et al. introduced a semi-supervised GCN model [24]. In this model, graph 
convolution operation on a graph was defined as a multi-layer propagation process. For the graph 
G = (V, E), an adjacency matrix A∈ℝN×N and a degree matrix D (𝑫𝑖𝑖 ൌ ∑ 𝑨𝑖𝑗𝑗 ) can be defined. The 
multi-layer model follows a layer-wise propagation rule as shown below: 
𝑯ሺ𝑙൅1ሻ ൌ σቆ𝑫෩െ12𝑨෩𝑫෩െ12𝑯ሺ𝑙ሻ𝑾ሺ𝑙ሻቇ              (1) 
Here, 𝑨෩ ൌ 𝑨൅ 𝑰  is the adjacency matrix 𝑨  of the undirected graph G with added self-
connections, I is the identity matrix, 𝑫෩𝑖𝑖 ൌ ∑ 𝑨෩𝑖𝑗𝑗 , 𝑾ሺ𝑙ሻ is a layer-specific weight matrix that is able 
to be trained, σሺ∙ሻ  is characterized as the activation function (i.e. ReLUሺ∙ሻ ൌ maxሺ0, ∙ ሻ ), 
𝑯ሺ𝑙ሻ∈ℝN×D is the matrix of activations of the 𝑙th layer. Specially, 𝑯ሺ0ሻ ൌ 𝑿 (𝑿 is the feature matrix 
consisting of x1, x2,  x3, …, xN). This form of propagation rule can be motivated and the final 
outcome after k layers of feature vector xi is the embedding vector zi. A general GCN model can 
be considered as a function 𝒈ሺ𝑿, 𝑨ሻ  ൌ  𝒁 (𝒁 is the embedding feature matrix consisting of z1, z2,  
z3, …, zN). 
However, for the complex network-based drug-drug synergy prediction using the above 
mentioned GCN model, there is an obvious limitation. It considers only single node type and link 
type. This drawback restricts the usage of the GCN model in heterogenous networks. In 2018, 
Marinka et al. developed a multi-relational link prediction model called Decagon [15]. They 
applied this model to predict polypharmacy side effects and achieved state-of-the-art performance. 
In this study, we adopted the Decagon-based GCN algorithm, which is capable to extract 
information of different types of nodes and edges. For a given node in a graph, successive 
operations of graph convolutional layers integrate and transform information from its neighbors. 
In this architecture, the edges (vi, vj) from a given graph G = (V, E) are divided into r types. Hence, 
the new representation of the edges is (vi, r, vj). For instance, 964 different relation types of drugs 
(side effects) were considered in Decagon. We continued to use this strategy for efficiently 
aggregating information from different edge types. There are 3 types of interactions (r = 1, 2, 3) 
in our drug-drug synergy prediction. The layer-wise propagation rule can be formulated as: 
𝑯ሺ𝑙൅1ሻ ൌ σቆ∑ 𝑫෩෩െ12𝑨෩𝑫෩෩െ12𝑯ሺ𝑙ሻ𝑾𝑟ሺ𝑙ሻ𝑟 ቇ          (2) 
Here, 𝑫෩෩  is the adjusted Laplace matrix and 𝑫෩෩𝑖𝑗 ൌ 𝑁𝑟ሺ𝒗𝒊ሻ𝑁𝑟൫𝒗𝒋൯, where 𝑁𝑟ሺ𝒗𝒊ሻ is the number 
of the neighbors of node 𝒗𝒊 by link type r. This number is a constant for a given graph. 𝑾𝑟ሺ𝑙ሻ is a 
trainable edge type-specific weight matrix of layer l. The same input and output forms as original 
GCN are maintained in this architecture. The first input layer could be numerical features, 
adjacency information or unique code of each node such as one-hot. Finally, the feature vector xi 
of a given node 𝒗𝒊 arrives in the ultimate embedding space as zi.  
2.3. Matrix bilinear decoder 
After mapping each node into the embedding space, the primary task is to represent the drug-
drug synergy in the new space. This process is defined as decoding. The goal of decoding is to 
reconstruct edge or node labels by the integrated information from the embedding space. 
Voluminous methods have been introduced to decode the embeddings. Matrix factorization is one 
of the easiest and most efficient way to perform the operation. 
From the GCN encoder each node including either drugs or proteins is first encoded into a 
unique vector in the embedding space (Fig.3). Then we observe the embedding node set of all the 
drugs. Utilizing the embedding vectors zu and zv, the synergy score between drug u and drug v is 
calculated by the following matrix in the bilinear form: 
𝒔ሺ𝑢, 𝑣ሻ ൌ 𝒛௨்𝑹௖𝒛௩                         (3) 
Where 𝑹௖ is a cell line-specific matrix to decode edges from node embedding vectors. 𝑹௖ is 
also trainable. The training process of 𝑹௖ is based on the cell line-specific heterogenous network. 
This is due to two reasons. Firstly, the synergistic effect is experimentally measured in different 
cell lines. Secondly, we expect to acquire the prediction among all the drug combinations across 
all the cell lines. 𝒔ሺ𝑢,𝑣ሻ is the predicted synergy score of the combination of drug u and drug v. 
Not like the original Loewe synergy score, the predicted score is between 0 and 1. The higher 
value represents the larger potential of synergy. Using this approach, the matrix bilinear decoder 
is able to well comprehend the embedding space. 
 
2.4. Model construction 
To build the model for drug-drug synergy prediction, we first constructed the GCN deep 
encoder (Fig.1c and Fig.3). Our GCN encoder had an input layer and 4 hidden layers. Between 
each of two hidden layers, there was a ReLu activation function. The activation function of the last 
hidden layer was the sigmoid function: 
𝑓ሺ𝒚ሻ ൌ ଵ  ଵାୣష𝒚                            (4) 
Here, y is the output of previous layer and 𝑓ሺ𝒚ሻ is the embedding vector. 39 cell line specific-
heterogeneous networks were input into the GCN encoder and the output was 39 cell line specific-
embedding spaces including the embedding vectors for each drug.  
Then from the embedding space, matrix decoder performed the mathematic operations to 
decode all given embedding vectors mentioned above. The matrix decoding was the 5th hidden 
layer. Finally, the result of the decoder was a cell line-specific synergy score matrix.  
Optimization was implemented using the cross-entropy loss function: 
𝑳 ൌ െ ଵே∑ ሾ𝑦௜log 𝑠௜ ൅ ሺ1 െ 𝑦𝒊ሻ log ሺ1 െ 𝑠௜ሻሿ௜           (5) 
Here, 𝑦𝒊 is the real synergistic state of each drug combination, 𝑠௜ is the predicted synergy 
score for each combination, and N is the number of drug combinations respectively. 
Backpropagation was carried out from the final loss back to each of the previous layers (Fig.3). 
We trained our full model including all the trainable parameters by this end-to-end method. It has 
been shown that the end-to-end learning can greatly improve the model performance because all 
the trainable parameters receive the gradients from the loss function jointly [25]. In this study, the 
loss propagates through both the GCN encoder and matrix decoder. 
 
 
 
Fig.3. The workflow of GCN encoder and matrix decoder. There are 4 hidden layers in the GCN encoder. Between 
each of two hidden layers, there is a ReLu activation function. The output of the ReLu is the input for the next hidden 
layer. For the last hidden layer, we adopt a sigmoid activation function. The input of the GCN model is a graph and 
the output is an embedding vector for each node. Matrix decoder decodes the embedding vectors to predict the synergy 
score of any given drug combination. 
 
2.5 Model comparison  
To benchmark the performance of our method, we compared the GCN model to the other 
state-of-art machine learning and deep learning approaches, including support vector machine 
(SVM) [26], random forest [27], elastic net [28], and deep neural network (DNN) [29]. For the 
input features of these models, we utilized physiochemical properties of drugs including 1-D 
descriptors (i.e., molecular weight, molar refractivity, and logarithm of the octanol/water partition 
coefficient), 2-D descriptors (i.e., number of atoms, number of bonds, and connectivity indices), 
and fingerprints which represent unique molecular structure and properties in a particular complex 
form. We extracted these properties of each drug using the PaDEL software [30] with default 
settings. As a result, a total of 2,325 structural features were obtained to construct the feature vector 
for each drug. For a drug-drug pair, the two individual feature vectors were concatenated into a 
4,650-demisional input feature vector. 
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 In order to verify the power of graph structure in predicting drug-drug synergy, we also used 
the adjacency from the adjacency matrix as the features for DNN. For a given drug, the feature 
was the corresponding adjacency vector of the adjacency matrix in the cell-line specific 
heterogenous network. The true feature vector of a sample (drug-drug pair) was the concatenated 
vector of two drugs.  
The DNN models maintained similar architectures as the GCN to avoid extra factors. There 
were 4 hidden layers in both the DNN using adjacency-specific features and the DNN using 
physiochemical-related features. The number of nodes in each of the 4 hidden layers was 1280, 
640, 128, 48, respectively. For the activation function, ReLu was utilized between each of two 
hidden layers. The loss function was also cross-entropy loss. 
 
2.6. Model evaluation 
To evaluate the performance of our proposed GCN model, proper sampling methods were 
considered since k-fold cross validation in traditional machine leaning is not well compatible in 
complex network data. There are different sampling methods in graph-based problems. We used a 
recently developed method called negative sampling, which can precisely and robustly estimate 
the network-based model performance [31]. Specifically, in each cell line-specific heterogeneous 
network, we randomly sampled a fixed proportion (i.e., 10%) of drug-drug links [15]. Then random 
selection of edges was performed by randomly selecting nodes according to a sampling distribution 
[31,32]. In our model, 10% was set as the sampling rate.  
To compare the model performance of SVM, random forest, elastic net, DNN 
(physiochemical) and DNN (adjacency), which were based on matrix-like feature vectors, we 
carried out 10-fold cross-validation strategy [33] to obtain unbiased performance.  
Performance was evaluated individually in each cell line. Since we split the drug-drug links 
into training and testing edges by the negative sampling strategy, we utilized two performance 
metrics, that is, accuracy and area under the curve (AUC) of a receiver operating characteristic 
(ROC) curve, to measure the performance of our model. Accuracy is the proportion of drug-drug 
pairs that were correctly predicted. AUC indicates the general performance under different true 
positive rates (TPR, sensitivity) and false positive rates (FPR, 1-specificity). AUC is a robust 
metric at different discrimination cutoffs assigned to a given drug-drug pair for a synergy. AUC is 
a value between 0 and 1 and the larger the value the better the performance of the model. The 
synergy score was calculated over all the cell lines to obtain an averaged performance.  
2.7. Software and global parameters 
For deep learning-based methods (GCN and DNN), our software environment incorporated 
the Keras version 2.2.4 (with tensorflow 1.13.1 backend) from http://github.com/fchollet/keras, 
which is a high-level neural networks API, written in Python and capable of running fast parallel 
computing. For all machine learning-based approaches (SVM, random forest and elastic nets), we 
implemented scikit-learn version 0.21.2 (A powerful open source machined learning package in 
python) to achieve the performance. 
We set mini batch size as 256 to ensure fast training and high accuracy. 20% dropout rate and 
200 epochs of Adam optimizer [34] were used to avoid overfitting. The learning rate was set to 
0.0001. Other training parameters including degree of momentum, strength of parameter 
regularization and initial weights were updated and optimized at the same time to reach optimal 
performance. 
 
3. Results 
3.1. Selection of the measured drug synergy score threshold 
To construct the cell line-specific heterogeneous networks, we first selected the optimized 
synergy score threshold through the negative sampling strategy. The performance was analyzed 
for a series of synergy score thresholds from 0 to 60. This pre-predictive evaluation was performed 
by the averaged AUC across all the cell lines. Basic GCN model was utilized to train the model. 
As shown in Fig.4, the best performance was obtained when the synergy score threshold was set 
at 30.  
Using the synergy score threshold of 30, we sequentially kept the drug-drug pairs with the 
scores equal or larger than 30 in the heterogeneous network. Cell line-specific networks were then 
constructed by using the links in a given cell line. 2,081 drug-drug pairs from 39 cell lines and six 
distinct tissue types were included.  
 
Fig. 4. The performance of different synergy thresholds. The performance measured by AUC was analyzed for 
synergy scores from 0 to 60 and the best threshold was obtained at 30 
3.2. Cell line-specific drug synergy prediction 
The trained model was used to predict the synergy scores of all drug combinations included 
in the network. The predicted values range from 0 to 1 and can be treated as probabilities to 
measure the synergy status of the drug combinations. According to the definition of Loewe synergy 
score, any score greater than 0 indicates the synergistic effect between the two drugs. In our 
predictions, this critical value was set to 0.5 since drug combinations with higher synergy score 
are of high value in experimental validation and clinical research.  
In order to assess the performance of our model, we calculated the sensitivity and specificity 
for each cell line at different probability thresholds. The ROC curves were drawn and the AUC 
was obtained for each cell line (Fig.5). The average AUC across cell lines is 0.84, with COAV3 
showing the largest AUC of 0.93 while COLO320DM showing the smallest AUC of 0.61. The 
accuracy for all cell line-specific GCNs were also calculated (Fig.5), resulting in a mean accuracy 
of 0.90. COLO320DM has the highest accuracy of 0.96 while MSTO has the lowest accuracy of 
0.83. In general, the accuracy and AUC of the GCN models for most cell lines are stable and the 
majority of these models have high accuracy and AUC (e.g., > 0.80), suggesting the overall 
performance of our model is excellent. Furthermore, in a small proportion of the cell lines, the 
performance is perfect. This varied prediction performance indicates that the drug-drug synergy is 
highly dependent on the characteristics of cell lines and tissues.  
 
 
 
Fig.5. The performance of DDS prediction for all cell lines. Both ACC (accuracy) and AUC are shown in the same 
coordinate system. The x-axis is the cell line index. The y-axis is numeric from 0 to 1. 
 
3.3. Investigation of prediction performance among tissues and drugs 
To further understand the varied performance, we evaluated the correlation of the observed 
synergy scores and the predicted synergy scores at tissue and drug levels, respectively. We utilized 
Pearson correlation coefficient, a powerful and understandable method to check the consistency 
between the two variables, to further investigate the variability. 
By integrating the predicted synergy scores with the measured synergy scores in the 39 cell 
lines from six tissues, we calculated the Pearson correlation (Fig.6a). The median of the 
coefficients is 0.64 for melanoma, 0.83 for ovarian, 0.67 for lung, 0.59 for colon, 0.71 for breast, 
and 0.68 for prostate. Among all the tissues, cell lines from ovarian show the highest median 
whereas those from prostate show the most concentrated distribution. The relatively high 
correlation suggests our model’s consistency in tissue-wise aspects.  
We further investigated the drug-wise correlation between predicted and measured synergy 
scores. For each drug, the correlation coefficient was averaged across all cell lines and existing 
drug combinations. The coefficients of drugs ranged from 0.39 to 0.90 (Fig.6b). For example, 
dasatinib used for treatment of chronic myeloid leukemia [35] has the highest correlation 
coefficient of 0.89. MK-2206, zolinza and MK-8669 also exhibit high correlation in the drug-
specific prediction. The drug-wise analysis suggests that complicated pharmacological actions 
contribute to the variability of drug-drug synergy prediction. 
 
Fig.6. The Pearson correlation coefficients of the GCN models. (a) The boxplot shows the Pearson correlation 
coefficients between true and predicted synergy scores per tissue types. On the x-axis the tissue names are displayed. 
(b) The bar plot shows the Pearson correlation coefficients between true and predicted synergy scores per drugs. On 
the x-axis the drug names are displayed. The error bar is shown for each drug. 
 
3.4 Data visualization and regression analysis 
To better understand the consistency of the drug combinations in different cell lines at the 
same time, we constructed the 3-D matrix to illustrate the synergy distribution. Both experimental 
(blue dots) and predicted (orange dots) data were shown together in Fig.7a. Generally speaking, 
data from the two measurements indicate the similar patterns. Since the predicted scores covered 
a b
both training and testing data, the 3-D synergy score distribution significantly supports that our 
model was well-trained and reached relatively high accuracy in the testing data.  
Furthermore, in order to eliminate the potential bias in regression and illustrate the synergy 
score distribution more properly, we scaled the experimentally observed Loewe synergy scores to 
a fixed range of 0 to 1 using the min-max scaling method. We regressed the predicted synergy 
scores on the normalized measured synergy scores, which is shown in Fig.7b with an R-squared 
value of 0.768 (p-value < 0.05). This demonstrates that the predicted synergy score is highly 
consistent with the measured ones. 
 
 
Fig. 7. The diagram of visualization and regression. (a) The 3-D matrix representation for experimentally measured 
drug synergy scores and predicted drug synergy scores. Each dot represents an experimental (blue, cutoff = 60, more 
than 60) or a predicted (orange, cutoff = 0.75) measurement of the synergy effect of drugs A and B in a specific cell 
line. The x axis is first drug index. The y axis is the second drug index. The z axis is the cell line index. (b) The 
regression of the predicted and measured synergy scores for all cell lines. Dots here are also flattened dots from the 
two 3-D matrices. The x-axis is the normalized measured synergy scores and y-axis is the predicted synergy 
probability (from 0 to 1). 
 
3.5. Model comparison 
We compared our GCN model with other four baseline methods. The mean and standard 
deviation (SD) of accuracies and AUCs of all cell lines for each method are listed in Table 2. The 
standard deviation can indicate the models’ robustness. Our proposed GCN approach achieved the 
best performance in terms of both accuracy and AUC. The GCN method demonstrated an 
improvement of 11% in its AUC compared to the second-best method, which is the adjacency-
based DNN. We believe this is because our GCN model successfully utilized the interconnections 
between heterogenous nodes. Among the four baseline methods, the DNN approach using either 
the adjacency features or the physiochemical features also showed a decent result. The DNN model 
with the physiochemical features was slightly better than that with the adjacency features in terms 
of AUC. Additionally, we also found that the performance of deep learning-based methods is better 
than that of other relatively traditional machine learning-based methods.  
Table 2 Performance of different classification methods. The reported Accuracy of AUC are the average of those 
for all cell lines. 
Method 
Accuracy AUC 
mean SD mean SD 
GCN 0.91 0.02 0.84 0.04 
DNN (adjacency) 0.88 0.03 0.75 0.05 
DNN (physiochemical) 0.83 0.05 0.81 0.02 
SVMs 0.87 0.06 0.76 0.07 
Elastic Nets 0.88 0.05 0.74 0.06 
Random Forests 0.87 0.04 0.78 0.05 
 
3.6. De novo prediction of drug synergy for particular cell lines 
The drug pairs with the highest predicted probability for synergy were selected for each cell 
line. Of these 39 drug pairs, the BEZ-235/MK-2206 combination and the oxaliplatin/sunitinib 
combination ranked highest for the colon cancer cell line COLO320DM and the lung cancer cell 
line NCIH520, respectively. However, both of the two pairs show a low predicted probability of 
0.1, and were thus removed. The remaining cell line-specific top predictions are listed in Table 3. 
To further examine the reliability of these top predicted drug combinations, we performed an in-
depth literature survey and found that many of these pairs have been reported to show synergistic 
effects in cancer treatment. For instance, bortezomib and dasatinib have been used as lung cancer 
therapy recently (i.e. small cell lung cancer and non-small cell lung cancer) according to the studies 
[36,37]. Although some literatures reported that there was lung toxicity when using these two 
drugs [6,38], our model predicted them to have synergistic effect in lung cancer cell lines. Evidence 
from both cell line-level experiments [39] and clinic trials [40] indicate bortezomib has synergistic 
effect with dasatinib by inhibiting cell viability and promoting apoptosis within dasatinib-treated 
cells. This evidence is an example that our de novo predictions of drug-drug synergy are strongly 
supported by previous experiments. 
 
Table 3 Top predicted synergistic drug combinations for each of the 39 cancer cell lines. Colon cancer cell line 
COLO320DM and the lung cancer cell line NCIH520 were not included in the table due to the low predicted 
probability synergy score of the top drug combinations in the two cell lines. 
Cell line Cancer Drug A Drug B Probability for synergy 
OCUBM Breast ABT-888  MK-8669 0.98 
ZR751 Breast AZD1775  BEZ-235 0.92 
MDAMB436 Breast BEZ-235 Temozolomide 0.86 
T47D Breast Sunitinib  BEZ-235 0.86 
KPL1 Breast MK-8669  MK-2206 0.82 
EFM192B Breast Dasatinib  MK-8669 0.78 
HT29 Colon MK-4827 Temozolomide 0.95 
RKO Colon MK-2206  MK-8669 0.88 
SW620 Colon Dasatinib  Sunitinib 0.87 
SW837 Colon Lapatinib  MK-2206 0.87 
HCT116 Colon BEZ-235  MK-8776 0.82 
LOVO Colon Lapatinib  Dasatinib 0.82 
DLD1 Colon Sunitinib Temozolomide 0.73 
SKMES1 Lung MK-4827  SN-38 0.93 
NCIH460 Lung BEZ-235  MK-4827 0.90 
MSTO Lung Bortezomib  Dasatinib 0.87 
NCIH23 Lung Temozolomide  MK-4827 0.84 
A427 Lung MK-8669 Temozolomide 0.82 
NCIH1650 Lung Dasatinib  MK-8669 0.81 
NCIH2122 Lung MK-4827 Temozolomide 0.68 
NCIH520 Lung Oxaliplatin  Sunitinib 0.10 
SKMEL30 Melanoma MK-8776  MK-8669 0.98 
A375 Melanoma BEZ-235  Temozolomide 0.96 
UACC62 Melanoma MK-8669  MK-4827 0.96 
A2058 Melanoma MK-8776 Temozolomide 0.89 
RPMI7951 Melanoma AZD1775  MK-8669 0.84 
HT144 Melanoma BEZ-235  MK-8669 0.62 
OV90 Ovarian Vinorelbine  MK-8776 0.97 
PA1 Ovarian BEZ-235  MK-4827 0.94 
SKOV3 Ovarian MK-8669  MK-4827 0.93 
UWB1289BRCA1 Ovarian BEZ-235  Temozolomide 0.91 
A2780 Ovarian MK-8669  MK-2206 0.85 
CAOV3 Ovarian Etoposide  MK-2206 0.83 
OVCAR3 Ovarian Dasatinib  MK-8776 0.82 
UWB1289 Ovarian AZD1775  BEZ-235 0.80 
ES2 Ovarian Sunitinib  BEZ-235 0.75 
VCAP Prostate BEZ-235  MK-4541 0.93 
LNCAP Prostate BEZ-235 Geldanamycin 0.77 
3.7. Exploration of embedding space of drug synergy prediction 
From the decoder, we obtained the embedding vector for each drug based on the cell line 
specific heterogeneous network. The embedding space represents the predictions to some extent. 
Hence, we used a data dimension reduction method t-SNE to further explore the potential hidden 
patterns in this space [41]. 
The t-SNE method is able to cluster embedding vectors of drugs into a visible space such as 
2D Euclidean space. We showed the result of t-SNE in a particular embedding space of cell line 
COLO320DM in Fig.8. It shows the drugs with higher probability of the synergistic effect, such 
as MK-8669/MK-2206 and sunitinib/dasatinib, were clustered together in the 2-D space. MK-8669 
and MK-2206 share a short distance in the cluster and their synergistic effect has been reported by 
a previous study [42].  
 
Fig. 8. Visualization of synergistic effects by t-SNE to explore the embedding space. The left panel (a) is the t-SNE 
result of the cell line KPL1-specific embedding space and the right panel (b) is the t-SNE result of the cell line SW620-
specific embedding space. Two red frames in the middle are the magnifications in particular areas in (a) and (b). The 
x-axis is the first dimension of t-SNE and the y-axis is the second dimension of t-SNE. Each dot is a representation of 
a specific drug. 
 
4. Discussion 
Given the enormous number of drug combinations, experimentally screening all possible 
pairs is unfeasible in terms of cost and time. Thus, computational methods have been extensively 
used to predict potential synergistic drug combinations. In this study, we have developed a GCN-
based model, which can predict synergy scores of drug combinations in particular cancer cell lines. 
Although it has been widely used in social network and knowledge graph prediction problems, 
GCNs have not until recently been introduced to the field of computational biology to predict sides 
effects caused by drug-drug interactions [15]. GCNs have not yet been used for prediction 
problems in drug synergy. Our GCN-based model for predicting synergistic drug combination was 
trained for each cell line and demonstrated a high accuracy, with a mean AUC of 0.84 (the 
minimum is 0.61, the maximum is 0.93) and a mean ACC of 0.91 (the minimum is 0.83, the 
maximum is 0.96), respectively. When treating the prediction task as a regression instead of a 
classification problem, the mean Pearson correlation coefficient between the measured and the 
predicted synergy scores of our GCN method for drug pairs in all cell lines was 0.70. 
It is noteworthy that the GCN models from some cell lines performed better than others in 
terms of AUC. As an example, models for the CAOV3 (ovarian cancer) and A427 (lung cancer) 
cell lines are the two best-performing ones among the 39 cell line-specific GCN models, with an 
AUC larger than 0.90. The variability could be partly explained by the difference in the number of 
all conceivable drug combinations from each cell line. For example, some cell lines comprise ~700 
tested drug combinations whereas others include approximate 500 screened drug combinations, 
leading to the varying training set size among cell lines. In addition, each cell line constitutes a 
different problem instance in this study. Even if training set size, features and classifiers are the 
same, the modeled relationship between drug synergy and features depends on training set 
composition and cell line properties due to the fact that the performance of supervised learning 
algorithms varies depending on the problem instance [43]. 
Among the top predicted drug pairs for the 39 cell lines (Table 2), many of them have been 
reported to be synergistic in the literature. For example, MK-8669 is a mTOR inhibitor [44] while 
MK-2206 is an Akt inhibitor [45]. For the estrogen receptor (ER)-positive breast cancer cell line 
KPL1 [46], the combination of these two agents shows the highest predicted synergy score, which 
is in accordance with a phase I clinical trial [42]. In this clinical study [42], a combination of MK-
8669 and MK-2206, with the aim to completely block the PI3K/Akt/mTOR signaling pathway 
required for tumor growth, showed promising activity and good tolerability in ER-positive breast 
cancer patients with the PI3K/Akt/mTOR pathway addiction. The combination of MK-8669 and 
MK-2206 also shows the highest synergistic score predicted by both the RKO- and A2780-specific 
GCN models. RKO is a colon cancer cell line while A2780 is an ovarian cancer cell line. Since 
the PI3K/Akt/mTOR signaling pathway is aberrantly activated to sustain the growth and survival 
of tumor cells in many cancer types, including human breast, colon, and ovarian cancers [47], MK-
8669 in combination with MK-2206 may act synergistically to block the PI3K/Akt/mTOR 
pathway in colon and ovarian cancer cells. For another triple negative breast cancer (TNBC) cell 
line MDAMB436 [48], BEZ-235 and temozolomide were predicted as the top synergistic pair. 
BEZ-235 is a novel dual PI3K and mTOR inhibitor and has been widely used in preclinical studies 
for various cancers including glioblastoma multiforme (GBM), breast, colorectal and lung cancers 
[49]. Temozolomide is a DNA alkylating agent and has been reported to induce cell apoptosis by 
the inhibition of mTOR signaling in GBM cells [50]. Compared with temozolomide or BEZ-235 
monotherapy, a combination of the two drugs has been found to more effectively inhibit GBM cell 
proliferation, invasion, migration and induce apoptosis in vitro by repressing the PI3K/Akt/mTOR 
pathway singling activity [51]. The PI3K/Akt/mTOR signaling pathway is one of the most 
frequently altered pathways in TNBC [52]. Thus, the combination of temozolomide and BEZ-235 
may be an effective treatment for TNBC, for which very limited targeted therapies exist currently. 
The combination of BEZ-235 and temozolomide was also predicted as the top synergistic pair for 
another two cell lines, the melanoma cell line A375 and the ovarian cancer cell line 
UWB1289BRCA1, for which constitutive PI3K/Akt/mTOR pathway activation has been observed 
[47]. Thus, our data suggests that BEZ-235 combined with temozolomide may have the potential 
to treat melanoma and ovarian cancer patients. Another combination of bortezomib and dasatinib 
has been predicted as synergistic pair in the lung cancer cell line MSTO by our GCN model and 
has experimentally shown synergistic antitumor activity in myeloma cell lines [53] and 
gastrointestinal stromal tumor cell lines [39]. Bortezomib is a small-molecule proteasome inhibitor 
and has activity in lung cancer both as a single drug and in combination with drugs commonly 
used in lung cancer [54]. Dasatinib is an inhibitor of Src family kinases and has modest clinical 
activity in lung cancer patients as a single drug in a phase II study [55]. Therefore, the combination 
of dasatinib and bortezomib may improve the treatment of lung cancer. The GCN model has also 
predicted some novel synergistic drug combinations, such as BEZ-235/geldanamycin in LNCAP 
(prostate cancer) and BEZ-235/MK-4541 in VCAP (prostate cancer). Geldanamycin is the first 
natural HSP90 inhibitor and has demonstrated antiproliferative and cytotoxic effects in 
both  human prostate cancer cell lines [56] and prostate xenograft tumors [57]. The PI3K/mTOR 
dual inhibitor BEZ-235 combined with an HSP90 inhibitor (NVP-AUY922) has been reported to 
act synergistically to inhibit tumor cell proliferation and induce apoptosis in cholangiocarcinoma 
cell lines [58]. HSP90 is often overexpressed in prostate cancer cells, making it a potential 
therapeutic target for prostate cancer [59]. The PI3K/Akt/mTOR pathway also plays an important 
role in prostate cancer cell survival, apoptosis, metabolism, motility, and angiogenesis [47]. These 
findings suggest that the combination of BEZ-235/geldanamycin may exhibit synergistic 
antitumor activity against prostate cancer, for which further experimental validation is needed. 
MK-4541 is a novel selective androgen receptor modulator and found to exert anti-androgenic 
activity in the prostate cancer xenograft mouse model [60]. Androgens are critical for the 
development, growth, and maintenance of male sex organs and can drive prostate cancer  initiation 
[60]. Therefore, the dual PI3K/mTOR inhibitor BEZ-235 might synergize with the androgen 
receptor inhibitor MK-4541 to treat prostate cancer. 
Although a large publicly available synergy dataset has been used in this study [4], there is a 
limited number of different cell lines, drugs, and drug combinations. In this cell line-specific GCN 
method, some drugs have been tested in combination with only a few other drugs. This means 
these drugs do not have a good number of links with other drugs for the neural network model to 
be trained. Therefore, we removed these drugs in the cell line(s), which led to a decrease in the 
train set size. However, this limitation can be overcome as more HTS drug combination datasets 
are generated.  
5. Conclusions 
In this study, we utilized the graph convolutional network method to develop GCN models, 
which can predict synergistic drug combinations for 39 cell lines derived from six major cancer 
types, including breast, colon, lung, melanoma, ovarian, and prostate cancers. For the 39 cell line-
specific GCN models we built, the mean AUC is 0.84 while the mean Pearson correlation 
coefficient between the measured and the predicted synergy scores is 0.70. Remarkably, we found 
that many synergistic combinations among our top predictions for a particular cancer type have 
been reported in the treatment of the same or other cancer types in the literature. Overall, given 
the prediction performance, the GCN models could be a valuable in silico tool for predicting novel 
synergistic drug combinations and thus guide in vitro and in vivo discovery of rational combination 
therapies. 
 
Abbreviation 
GCN Graph Convolutional Network 
AUC area under the curve 
HTS high throughput screening 
RF random forest 
XGBoost extreme gradient boosting 
DDS drug-drug synergy 
DTI drug-target interaction 
PPT protein-protein interaction 
CNN convolutional neural network 
ROC receiver operating characteristic 
TPR true positive rate 
FPR false positive rate 
SVM support vector machine 
DNN deep neural network 
ACC accuracy 
SD standard deviation 
ER estrogen receptor 
TNBC triple negative breast cancer 
GBM glioblastoma multiforme 
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